Literature DB >> 22231754

Hematological cancer in 2011: New therapeutic targets and treatment strategies.

Paula Cramer1, Michael Hallek.   

Abstract

2011 saw improvements in our understanding of B-cell malignancies: insights into the genomic basis of chronic lymphocytic leukemia were achieved; reduced treatment intensity caused fewer toxic effects in early-stage Hodgkin lymphoma; first-line rituximab maintenance therapy improved outcome in follicular lymphoma; and selected patients with diffuse large-cell lymphoma benefited from the addition of bortezomib.

Entities:  

Mesh：

Year:  2012        PMID： 22231754     DOI： 10.1038/nrclinonc.2011.212

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Authors:  Andreas Engert; Annette Plütschow; Hans Theodor Eich; Andreas Lohri; Bernd Dörken; Peter Borchmann; Bernhard Berger; Richard Greil; Kay C Willborn; Martin Wilhelm; Jürgen Debus; Michael J Eble; Martin Sökler; Antony Ho; Andreas Rank; Arnold Ganser; Lorenz Trümper; Carsten Bokemeyer; Hartmut Kirchner; Jörg Schubert; Zdenek Král; Michael Fuchs; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Volker Diehl
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

2.  Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

Authors:  Jia Ruan; Peter Martin; Richard R Furman; Shing M Lee; Ken Cheung; Julie M Vose; Ann Lacasce; Julia Morrison; Rebecca Elstrom; Scott Ely; Amy Chadburn; Ethel Cesarman; Morton Coleman; John P Leonard
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

3.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors:  Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal:  Nature       Date:  2011-06-05       Impact factor: 49.962

4.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321

5.  Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.

Authors:  Emmanuel Bachy; Pauline Brice; Richard Delarue; Nicole Brousse; Corinne Haioun; Steven Le Gouill; Alain Delmer; Dominique Bordessoule; Hervé Tilly; Bernadette Corront; Christian Allard; Charles Foussard; André Bosly; Bertrand Coiffier; Christian Gisselbrecht; Philippe Solal-Celigny; Gilles Salles
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

6.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

Authors:  Lili Wang; Michael S Lawrence; Youzhong Wan; Petar Stojanov; Carrie Sougnez; Kristen Stevenson; Lillian Werner; Andrey Sivachenko; David S DeLuca; Li Zhang; Wandi Zhang; Alexander R Vartanov; Stacey M Fernandes; Natalie R Goldstein; Eric G Folco; Kristian Cibulskis; Bethany Tesar; Quinlan L Sievers; Erica Shefler; Stacey Gabriel; Nir Hacohen; Robin Reed; Matthew Meyerson; Todd R Golub; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  N Engl J Med       Date:  2011-12-12       Impact factor: 91.245

7.  Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia.

Authors:  Yoshikane Kikushige; Fumihiko Ishikawa; Toshihiro Miyamoto; Takahiro Shima; Shingo Urata; Goichi Yoshimoto; Yasuo Mori; Tadafumi Iino; Takuji Yamauchi; Tetsuya Eto; Hiroaki Niiro; Hiromi Iwasaki; Katsuto Takenaka; Koichi Akashi
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

8.  ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Authors:  Simonetta Viviani; Pier Luigi Zinzani; Alessandro Rambaldi; Ercole Brusamolino; Alessandro Levis; Valeria Bonfante; Umberto Vitolo; Alessandro Pulsoni; Anna Marina Liberati; Giorgina Specchia; Pinuccia Valagussa; Andrea Rossi; Francesco Zaja; Enrico M Pogliani; Patrizia Pregno; Manuel Gotti; Andrea Gallamini; Delia Rota Scalabrini; Gianni Bonadonna; Alessandro M Gianni
Journal:  N Engl J Med       Date:  2011-07-21       Impact factor: 91.245

9.  Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.

Authors:  Peter Borchmann; Heinz Haverkamp; Volker Diehl; Thomas Cerny; Jana Markova; Anthony D Ho; Hans-Theodor Eich; Hans Konrad Mueller-Hermelink; Lothar Kanz; Richard Greil; Andreas Rank; Ursula Paulus; Lenka Smardova; Christoph Huber; Bernd Dörken; Christoph Nerl; Stefan W Krause; Rolf-Peter Mueller; Michael Fuchs; Andreas Engert
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544
  9 in total
  8 in total

1.  MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.

Authors:  Juan J Gu; Francisco J Hernandez-Ilizaliturri; Cory Mavis; Natalie M Czuczman; George Deeb; John Gibbs; Joseph J Skitzki; Ritesh Patil; Myron S Czuczman
Journal:  Anticancer Drugs       Date:  2013-11       Impact factor: 2.248

2.  Pain Phenotypes and Associated Clinical Risk Factors Following Traumatic Amputation: Results from Veterans Integrated Pain Evaluation Research (VIPER).

Authors:  Thomas Buchheit; Thomas Van de Ven; Hung-Lun John Hsia; Mary McDuffie; David B MacLeod; William White; Alexander Chamessian; Francis J Keefe; Chester Trip Buckenmaier; Andrew D Shaw
Journal:  Pain Med       Date:  2016-01       Impact factor: 3.750

Review 3.  CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).

Authors:  Sarah K Tasian; Rebecca A Gardner
Journal:  Ther Adv Hematol       Date:  2015-10

4.  A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Authors:  Giovanni F Torelli; Carmela Rozera; Laura Santodonato; Nadia Peragine; Giuseppina D'agostino; Enrica Montefiore; Maria R Napolitano; Domenica M Monque; Davide Carlei; Paola Mariglia; Simona Pauselli; Maria Gozzer; Mahnaz Shafii Bafti; Gabriella Girelli; Anna Guarini; Filippo Belardelli; Robin Foà
Journal:  Blood Transfus       Date:  2015-01-30       Impact factor: 3.443

Review 5.  Investigative and clinical applications of synthetic immune synapses.

Authors:  Michael C Milone; Lance C Kam
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-08-23

6.  POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia.

Authors:  Andrew J Ramsay; Víctor Quesada; Miguel Foronda; Laura Conde; Alejandra Martínez-Trillos; Neus Villamor; David Rodríguez; Agnieszka Kwarciak; Cecilia Garabaya; Mercedes Gallardo; Mónica López-Guerra; Armando López-Guillermo; Xose S Puente; María A Blasco; Elías Campo; Carlos López-Otín
Journal:  Nat Genet       Date:  2013-03-17       Impact factor: 38.330

7.  Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia.

Authors:  Annalisa Pezzolo; Danilo Marimpietri; Lizzia Raffaghello; Claudia Cocco; Angela Pistorio; Claudio Gambini; Michele Cilli; Alberto Horenstein; Fabio Malavasi; Vito Pistoia
Journal:  Oncotarget       Date:  2014-11-15

Review 8.  Mechanisms of epigenetic regulation of leukemia onset and progression.

Authors:  Panagiotis Ntziachristos; Jasper Mullenders; Thomas Trimarchi; Iannis Aifantis
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.